Cite
HARVARD Citation
Garcia-Sanz, R. et al. (2019). Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group). Annals of oncology. pp. 612-620. [Online].